- Molecular NameBleomycin
- SynonymBleocin; Bleomicin; Bleomicina [INN-Spanish]; Bleomycin A2; Bleomycin B2; Bleomycin sulfate; Bleomycine [INN-French]; Bleomycinum [INN-Latin]; BLM
- Weight1312.36
- Drugbank_IDDB00290
- ACS_NO11056-06-7
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)N/A
- pkaN/A
- LogD (pH=7, predicted)N/A
- Solubility (experiment)Soluble
- LogS (predicted, ACD/Labs)(ph=7)N/A
- LogSw (predicted, AB/LogsW2.0)N/A
- Sw (mg/ml) (predicted, ACD/Labs)N/A
- No.of HBond DonorsN/A
- No.of HBond AcceptorsN/A
- No.of Rotatable BondsN/A
- TPSAN/A
- StatusFDA approved
- AdministrationIntramuscular and subcutaneous
- PharmacologyA glycopeptide antibiotic produced by the bacterium Streptomyces verticillus. Bleomycin refers to a family of structurally related compounds. When used as an anti-cancer agent, the chemotherapeutical forms are primarily bleomycin A2 and B2.
- Absorption_valueN/A
- Absorption (description)It is poorly absorbed after oral administration.
- Caco_2N/A
- BioavailabilityN/A
- Protein binding1.0
- Volume of distribution (VD)0.35 to 0.45 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmMost tissues, except skin and lung, can degrade bleomycin enzymically.
- Half life2~4 h
- Excretion70% is excreted in urine as the active drug.
- Urinary ExcretionN/A
- Clerance119 to 128 ml/min/m2.
- ToxicityPulmonary toxicity is the most serious adverse effect and is more likely in those given total cumulative doses greater than 400 units.
- LD50 (rat)N/A
- LD50 (mouse)N/A